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Abstract
Background: Endothelial dysfunction (ED) is an independent predictor of cardiovascular events.
ED is also a reversible disorder, and nitric oxide donors like L-arginine may promote this process.
Despite the positive results from several studies, there are some studies that have shown that L-
arginine administration did not improve endothelium-dependent dilation or the inflammatory state
of patients. In this study the early and the late effects of L-arginine on coronary fatty streak
formation and ED biomarkers were considered in hypercholesterolemic rabbits.
Methods: 36 white male rabbits randomly assigned in 3 groups. Rabbits were fed 1% high-
cholesterol diet (LP group, n = 15), or high-cholesterol diet with oral L-arginine (3% in drinking
water) (EP group, n = 15) or standard diet (control group, n = 6) for 4 weeks (phase I). Afterward,
all animals were fed normal diet for 4 weeks (phase II). In the second phase, L-arginine was
discontinued for EP group and was begun for LP group. The plasma levels of lipids, von Willebrand
factor (vWF), and nitrite were compared before and after 4 and 8 weeks of experiment. Coronary
fatty streak formation was measure after 4 and 8 weeks of experiment.
Results: The plasma levels of lipids were increased significantly in both groups of LP and EP after
phase I. The hypercholesterolemia induced significant increased vWF release in LP group. The L-
arginine supplementation led to significant plasma nitrite increment in EP group. The vWF in LP
group was higher than other groups (p < 0.05). By the end of phase II, despite of start of L-arginine
supplementation for LP group and L-arginine discontinuation in EP group, there were significantly
more fatty streaks lesions in LP group coronary arteries than EP group. Furthermore, L-arginine
supplementation did not result in significant nitrite increment in LP group.
Conclusion: Early prevention by L-arginine may be helpful to prevent the ED, but our study did
not suggest the treatment. It seems reasonable to consider ED-aside from control the
cardiovascular risk factors in primary prevention of atherosclerosis and its clinical outcomes before
development of irreversible vascular damage.
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Background
Atherosclerosis is the single most important cause of car-
diovascular disease (CVD) – a predominant health prob-
lem worldwide[1]. Clinical manifestations of
atherosclerosis include myocardial infarction, heart fail-
ure, stroke, and peripheral artery disease, result in irrevers-
ible organ damage[2]. Early atherosclerosis lesions or fatty
streaks become increasingly prevalent among children
and young adults in industrialised countries[3,4]. Fatty
streaks lesion formation may begin even before birth as
intimal thickening can be observed in fetal coronary arter-
ies[5]. Although these lesions may be vanishing, some of
these lesions progress to advanced stages of atherosclero-
sis. As atherosclerosis has a long asymptomatic phase and
the first manifestation of disease may be sudden cardiac
death, it is imperative to find effective strategies to prevent
it[4,6]. Current guidelines for the prevention of athero-
sclerotic diseases focus on treatment of established cardi-
ovascular risk factors to attenuate the subsequent
endothelial cell dysfunction and damage[6]. Endothelial
dysfunction (ED) is an early event in atherosclerosis and
has a pivotal role in the atherogenesis process[7].
ED is an independent predictor of cardiovascular events,
therefore it seems reasonable to be mentioned, aside from
risk factor modification in primary prevention[6,7]. Fur-
thermore ED is a reversible disorder and search for the
proper time before development of irreversible vascular
injury is extremely important [4].
ED is characterized by reduced bioavailability of nitric
oxide (NO) [8-11]. NO is a potent anti atherosclerotic
molecule and every intervention that enhances NO bioa-
vailability might be a promising strategy for the preven-
tion and treatment of atherosclerosis [10-13]. One
straightforward approach to increase NO bioavailability is
providing additional substrate for nitric oxide synthase
(NOS). L-Arginine is the substrate of endothelial NOS
(eNOS) and the main precursor of NO in the vascular
endothelium. Data from numerous studies imply that L-
arginine supplementation restores endothelial function in
several disease states associated with ED such as hyperc-
holesterolemia [14-18]. Despite the positive results from
several studies, there are some studies that have shown
that L-arginine administration did not improve endothe-
lium-dependent dilation or the inflammatory state of
patients [18]. L-arginine could even be harmful to vascu-
lar health; for example L-arginine supplementation dur-
ing the post-myocardial-infarction period was associated
with higher post-infarction mortality than placebo [19].
So, it is still unclear whether administration of L-arginine
has any beneficial effect on clinical outcome [18].
The present study is aimed to investigate the preventive
role of L arginine in two approaches: 1) L arginine supple-
mentation concurrently with cholesterol enriched diet,
and 2) L arginine supplementation four weeks later than
cholesterol enriched diet initiation and fatty streaks for-
mation in hypercholesterolemic rabbit's aortas.
Methods
Animals and Experimental design
This study was reviewed and approved by the Ethics Com-
mittee of Isfahan University of Medical Sciences. 36 white
male rabbits were obtained from the Razi Institute of Iran.
After 1-week acclimation period, and an overnight fasting
blood samples were taken as pre experiment sampling.
Collected blood samples were centrifuged (10,000 _ g),
and the resulting plasma was stored at -70°C until meas-
urements. The animals were then randomly assigned in 3
groups. The rabbits were fed rabbit chow supplemented
with 1% cholesterol (Hypercholesterolemic diet, Late pre-
vention group; LP, n = 15) or high-cholesterol diet with
oral L-arginine (3% in drinking water; Early prevention
group; EP, n = 15) or standard diet (control group, n = 6)
for 4 weeks. The cholesterol-enriched diet was prepared
daily on site by dissolving cholesterol in the olive oil and
thoroughly coating the pellets of rabbit chow with this
mixture [20]. The olive oil was also added to the pellets of
rabbit chow of control group. Each animal in each group
had daily access to 120 g of pellets. Water was available ad
libitum. The cholesterol and L-arginine were purchased
from Scharlau (Barcelona, Spain) and Ajinomoto Co
(Japan) respectively. The body weight determined before
experiment and at 4th and 8th weeks.
By the end of 4 weeks (phase I), the blood samples were
taken and stored again. Ten animals from each of EP and
LP groups and three animals from control group ran-
domly were selected and euthanized by an overdose of
sodium pentobarbital and exsanguinated. The animal's
hearts were harvested for pathological investigation. From
this point, hypercholesterolemic diet was break off and all
remainder animals were on normal diet, L-arginine sup-
plementation for EP group was stopped and oral L-
arginine supplementation (3% in drinking water) for LP
group was began. The experiment was continued for
another 4 weeks (phase II). At the end of the phase II, the
blood sampling and storage were repeated. The rest of the
animals were scarified and the hearts were harvested for
pathological investigation.
Lipid and lipoprotein measurements
Total cholesterol, triglyceride, high density lipoprotein
(HDL) and low density lipoprotein (LDL) cholesterol lev-
els were measured by standard enzymatic kit (Pars
Azmoon Co, Iran)
Plasma vWF and nitrite measurement
Von Willebrand factor (vWF), is a well-established in vivo
marker of endothelial cell activation and injury [21].
Plasma vWF was measured by sandwich enzyme-linkedNutrition & Metabolism 2009, 6:13 http://www.nutritionandmetabolism.com/content/6/1/13
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immuno-sorbent assay (ELISA) using paired capture and
detecting anti-vWF. antibodies (Cedarlane Co, Canada) as
previously described [21].
The plasma level of nitrite (stable NO metabolite) was
measured using a colorimetric assay kit (R&D Systems,
Minneapolis, USA) that involves the Griess reaction as
previously described [22].
Coronary fatty streaks or CSN determination
The hearts were fixed with 10% neutral buffered formalin
solution and embedded in paraffin. The paraffin blocks were
sectioned serially and serial sections prepared at 1000 μm
intervals were stained with haematoxylin and eosin. Using
an Olympus microscope equipped for projection, the sam-
pled sections of the coronary arteries were projected onto a
table top (at 100× magnification). An orthogonal grid (2 cm
× 2 cm) was superimposed over the projected image, and the
number of grid points overlying the intima, and lumen for
the coronary artery were counted by two independent
experts blinded to the experiment groups. The luminal area
and the area covered by intimal lesions were delineated. Cor-
onary cross sectional narrowing (CSN) was calculated using
the equation: CSN (%) = 100× the surface area of lesions/the
luminal area. The CSN shows the degree of fatty streaks for-
mation and atherosclerosis progression[23,24].
Statistical analysis
The data are reported as the mean ± SEM. A statistical soft-
ware package, SPSS (version 13), was used to perform sta-
tistical analysis. The data were tested for normality and
homogeneity of variance. ANOVA repeated measures
were used to assess within group changes and One-way
ANOVA followed by Bonferroni's t-test within groups
were used to assess the significance of any change between
groups. Non-parametric methods (Wilcoxon rank-sum
test and Kruskal-Wallis test) were used for the comparison
of CSN, within and between groups. Statistical signifi-
cance was accepted at p < 0.05.
Results
The effect of L-arginine on plasma levels of lipids and 
lipoproteins
The hyperlipidemia induced by dietary cholesterol in rab-
bits is owing to overproduction of lipoproteins and
impaired plasma clearance secondary to the down-regula-
tion of LDL receptor expression in rabbit's liver [25]. The
effect of 4 weeks high cholesterol diet on cholesterol and
LDL levels have been shown in table 1. Initial values for
lipids and lipoproteins were similar in all groups. The
cholesterol-rich diet induced a significant increase of total
cholesterol, LDL and HDL-cholesterol, and triglyceride
(TG) in both EP and LP groups (p < 0.05) through the first
phase of study. By the end of phase II, plasma cholesterol,
LDL and HDL reduced significantly but did not return to
baseline values in both EP and LP groups (Table 1). The
plasma TG level reduced significantly and there was no
difference between pre experiment and ending values
(Table 1). The lipid and lipoprotein levels in the control
group remained statistically unchanged through the
study. By the end of phase I, the animals of the EP and the
LP group had similar levels of cholesterol, LDL, HDL and
TG as well as by the end of phase II (p > 0.05); while all of
the lipids and lipoproteins in these 2 groups were signifi-
cantly higher than control group (p < 0.05) (Table 1).
These results showed that L arginine had no lipid lowering
effects in our study.
The effect of L-arginine on body weight
As shown in Table 1, in the beginning there were no sig-
nificant body weight differences between three groups of
the study. Both cholesterol-fed groups significantly gained
weight throughout the study; while there was no signifi-
cant weight gain in the control group. There was no signif-
icant weight gain difference between EP and LP groups
through the experiment. Thus, L-arginine did not affect
weight gain.
The effect of L-arginine on plasma level of nitrite
During the first phase, the plasma level of nitrite signifi-
cantly increased in EP group (p < 0.05), and it was also
significantly higher than other groups (p < 0.05) (table 1).
During the phase II, despite of the start of L-arginine sup-
plementation for LP group, there was no significant
change in nitrite concentration. The plasma nitrite con-
centration in EP and control groups also remained statis-
tically unchanged in this phase. Finally in phase II, there
was no significant difference in plasma level of nitrite,
between EP and LP groups; while both groups had signif-
icantly higher level of nitrite than control group (table 1).
The effect of L-arginine on plasma level of vWF
The plasma level of vWF significantly increased during the
first phase of experiment in LP group, and it was statisti-
cally different from others groups (p < 0.05) (table 1). By
the end of phase II, the plasma level of vWF significantly
decreased in EP and LP groups while the plasma level of
vWF remained unchanged in control groups (p < 0.05)
(table 1).
The effect of L-arginine on CSN; fatty streaks
Figure 1 shows measurements of the extent of atheroscle-
rotic lesions of the coronary arteries. Early atheromatous
lesions (fatty streaks) were seen in rabbit's coronary arter-
ies by the end of phase I. In this phase, there was no sig-
nificant difference in the CSN between the groups;
however, by the end of phase II the CSN of the EP group
was significantly lower than LP group. There was no fatty
streak lesion in control animals' coronary arteries during
the study.Nutrition & Metabolism 2009, 6:13 http://www.nutritionandmetabolism.com/content/6/1/13
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Table 1: The plasma levels of lipids, lipoproteins, nitrite, vWF and rabbit's body weights in three groups of the study in three sampling 
sessions. 
Parameter/group EP LP Control
Cholesterol
(mg/dl)
A 108.56 ± 20.1 94.13 ± 15.4 118.65 ± 12.1
I 1918.93 ± 245.4* 2291.68 ± 227.8* 138.38 ± 11.8 ‡
II 1275.00 ± 169.5* , † 1433.40 ± 161.3*, † 122.7 ± 10.5 ‡
Triglyceride (mg/dl) A 122.61 ± 2.3 121.42 ± 3.9 119.31 ± 2.7
I 228.12 ± 26.7* 232.4 ± 25.6* 121.89 ± 4.3‡
II 147.0 ± 17.2† 141.02 ± 15.6† 117.90 ± 3.2‡
LDL
(mg/dl)
A 28.35 ± 9.4 44.01 ± 10.8 33.5 ± 8.9
I 1079.66 ± 118.2* 1418.99 ± 189.6* 42.76 ± 10.7 ‡
II 623.18 ± 126.5*, † 635.09 ± 113.7*, † 38.6 ± 11.4 ‡
HDL
(mg/dl)
A 15 ± 2.4 15.5 ± 1.3 16.4 ± 1.7
I 109.6 ± 20.1* 96.1 ± 11.6* 18.3 ± 1.4‡
II 60.6 ± 11.2*† 74.0 ± 9.4*† 20.0 ± 3.2‡
Nitrite
(μM/l)
A 11.40 ± 1.0 11.11 ± .8 9.86 ± .8
I 14.7 ± .5*, ‡ 12.2 ± .7 9.86 ± .8
II 16.57 ± 1.2*, ‡ 14.58 ± 2 8.83 ± .2
vWF
(IU/dl)
A 0.55 ± .06 0.42 ± .09 0.32 ± .04
I 0.49 ± .04 0.99 ± .1 *, ‡ 0.35 ± .06
II .08 ± .006*, † .07 ± .006*, † 0.23 ± .04 ‡
Body weight
(kg)
A 2.15 ± 0.1 2.13 ± 0.2 1.87 ± 0.3
I 2.37 ± 0.2* 2.38 ± 0.1* 1.92 ± 0.2‡
II 2.51 ± 0.3† 2.45 ± 0.2† 2.0 ± 0.2‡
A: pre-test sampling, I: after 4 weeks (phase I) and II: after 8 weeks (phase II).
significant difference * from (A), † from (I); and ‡ from other groups (p < 0.05).Nutrition & Metabolism 2009, 6:13 http://www.nutritionandmetabolism.com/content/6/1/13
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Discussion
The aims of this study were to investigate the effect of L-
arginine as a NO donor on the atherosclerosis prevention
and search for the appropriate time for its beginning in a
rabbit model of hypercholesterolemia. We used the die-
tary reversal model of hypercholesterolemia because in a
realistic clinical setting the first-step therapy in hypercho-
lesterolemic patients is the lowering of cholesterol; so the
LP group is the equivalent of hypercholesterolemic
patients and the EP group is the equivalent of patients at
risk of developing hypercholesterolemia and atheroscle-
rosis.
The results showed that hypercholesterolemia induced
significant endothelial injury characterized by increased
vWF release within 4 weeks after initiation of a 1% choles-
terol diet in LP group. As we assumed L-arginine supple-
mentation augmented NO production in EP group in the
first phase of the study. In spite of the presence of hyperc-
holesterolemia, L-arginine preserved endothelium from
adverse effects of risk factor as substantiated by signifi-
cantly lower vWF in this group. This finding is in line of
previous studies in which NO restrained ED and injury
[9,11,13]. Several other studies that investigated L-
arginine beneficial effects on endothelial function, partic-
ularly in hypercholesterolemic animals, have supple-
mented L-arginine during induction of
hypercholesterolemia [17,26-28]. These studies are simi-
lar to EP group in our study and attained similar results.
These experiments showed that ingestion of L-arginine, as
a boosting supplement for NO production can reverse the
state of oxidative stress and progression of atherosclerosis.
Furthermore, as we have shown in our recently published
paper, the positive results of L-arginine on endothelial
function may be the consequence of enhanced expression
of eNOS in vessel wall [29].
By the end of phase II, significant fatty streak lesions were
formed in coronary arteries of LP groups. Despite of the
start of L-arginine supplementation for LP group and L-
Comparison of coronary crosses sectional narrowing (CSN) between EP and LP groups; Fatty streaks were seen in both  groups of rabbit's coronary arteries by the end of phase I Figure 1
Comparison of coronary crosses sectional narrowing (CSN) between EP and LP groups; Fatty streaks were 
seen in both groups of rabbit's coronary arteries by the end of phase I. In this phase, there was no significant differ-
ence in the CSN between the groups; however, by the end of phase II the CSN of the EP group was significantly lower than LP 
group. I: after 4 weeks (phase I) and II: after 8 weeks (phase II). LP: Late prevention, EP: Early prevention.
                   Significant difference from other group (p<0.05) 
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arginine discontinuation in EP group, there were signifi-
cantly more fatty streaks lesions in LP group coronary
arteries than EP group. This finding is interesting in light
of other findings that L-arginine supplementation did not
result in significant NO increment in LP group. This is in
agreement with other studies that have shown that L-
arginine did not improve endothelial function in patients
with coronary atherosclerosis or myocardial infarction
[30-32]. These findings suggest that L-arginine is effective
before exhaustive ED and vascular endothelium damage.
It seems that L-arginine supplementation is useful in vas-
cular bed with healthy and functional eNOS. It might
even be harmful if supplemented in situations with eNOS
uncoupling[18].
It is likely that we need to start effectual prevention much
earlier than previously assumed. Consistent with this
view, finding from paediatric studies complemented by
necropsy data demonstrate clearly that children and
young adults are also liable to the effects of cardiovascular
risk factors and show early signs of atherogenesis[3,5].
Furthermore, it has been shown that maternal hypercho-
lesterolemia is associated with greatly enhanced fatty
streaks formation in fetal arteries, both in human and ani-
mal models [33-35]. These observations may provide
rational for start prevention in childhood.
Conclusion
As the results of our study showed, L-arginine supplemen-
tation after induction of hypercholesterolemia may lead
to more coronary fatty streaks formation while L-arginine
was effective before exhaustive ED and vascular endothe-
lium damage. Early prevention by L-arginine may be help-
ful to prevent ED, but our study did not suggest the
treatment.
In addition, given the important role of ED for the devel-
opment of atherosclerosis, it seems reasonable to consider
ED-aside from control of the cardiovascular risk factors- as
a primary therapeutic target in the prevention of athero-
sclerotic disease. The observation that interventions such
as L-arginine supplementation improve endothelial func-
tion without altering the risk factor profile supports the
concept that the endothelium serves as a central trans-
ducer by which risk factors can mediate progression to
atherosclerosis, and its status may reflect the propensity to
develop atherosclerotic disease.
This study has several limitations. First, the rabbit model
in this study is a rapidly progressive model and we must
be cautious when we apply short-time outcome in animal
model to human slowly progressive disease, such as
atherosclerosis. A second potential limitation of our study
is the relatively small sample size. A third potential limi-
tation of the study is using only one dose of oral L
arginine. Furthermore, as the present study was designed
to assess the effects of L-arginine for 4 weeks, the long-
term effects of L-arginine need to be studied.
Further studies are needed to retrieve the right timing to
initiate primary prevention of atherosclerosis and its clin-
ical outcomes before development of irreversible vascular
damage.
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